Journal of Drugs in Dermatology最新文献

Background: Poly-l-lactic acid (PLLA) is an injectable biostimulatory filler used for restoring facial fat volume loss.

Objective: To evaluate the safety and efficacy of injectable PLLA injections for volume loss in the temples using dual plane injections. Assessments included live ratings and ratings of standardized pictures and ultrasound imaging at weeks 4, 8, 12, and 16 by a trained evaluator.

Results: At the 8-week follow-up, there was a statistically significant increase in temporal volume and improvement in skin elasticity in PLLA-treated subjects. Treatment was well-tolerated with minimal self-resolving adverse effects. Ultrasound imaging confirmed that the injection plane was free of vasculature, posing no safety risk.

Conclusion: Repeated PLLA treatments in the temporal region elicited a global improvement in facial shape, particularly the mid and upper face region. The temple hollowness and facial laxity improved over time with no safety sequelae.

Background: Skin aging results from intrinsic and extrinsic factors, including oxidative stress, ultraviolet (UV) radiation, and declining cellular functions. These factors lead to visible changes like rhytids, pigmentation, and loss of elasticity. Meanwhile, interest in plant-based skincare ingredients for skin aging has been increasing.

Objective: This systematic review investigates the anti-aging potential of Astragalus membranaceus, a botanical plant. The authors focused on its active components and their roles in dermal protection, antioxidant, anti-inflammatory, anti-aging properties, and telomere elongation.

Methods: A comprehensive PubMed search from 2015 to 2025 per PRISMA guidelines identified clinical and experimental studies assessing the anti-aging effects of Astragalus membranaceus.

Results: Bioactive compounds, including astragaloside IV, cycloastragenol, flavonoids, and polysaccharides, showed photoprotective effects, including reactive oxygen species (ROS) reduction, inflammatory signaling inhibition, mitochondrial preservation, and promotion of collagen synthesis. Elongation of telomeres under oxidative stress was also demonstrated with Astragaloside IV. Clinical trials showed improvements in skin hydration, tone, and wrinkle reduction.

Conclusion: Astragalus membranaceus offers promise as a botanical anti-aging agent. Its effects on collagen, oxidative defense, and telomere preservation support its potential use in cosmeceuticals. However, further randomized trials are needed to confirm long-term efficacy and safety.  .

Background: Topical efinaconazole 10% solution has demonstrated efficacy and safety in two phase 3 trials of onychomycosis. As clinical data for onychomycosis treatments are limited in patients with skin of color, this post hoc analysis evaluated efinaconazole in participants categorized by race.

Methods: Data were pooled from 2 multicenter, double-blind, phase 3 trials (NCT01007708, NCT01008033). Participants aged 18 to 70 years with mild-to-moderate distal lateral subungual onychomycosis in ≥1 great toenail were randomized (3:1) to once-daily efinaconazole or vehicle for 48 weeks. Efficacy endpoints at week 52 included rates of mycologic cure (MC; negative potassium hydroxide examination + negative fungal culture), complete cure (0% clinical involvement + MC), complete/almost complete cure (≤5% clinical involvement + MC), and clinical efficacy (<10% clinical involvement). Adverse events (AEs) were assessed.

Results: Participants (n=1655) were categorized by self-reported race: White (n=1251), Asian (n=269), or Black (n=98). At week 52, more efinaconazole- vs vehicle-treated participants achieved complete cure (White, 14.7% vs 2.0%; Asian, 27.5% vs 13.0%; Black, 12.9% vs 7.1%), complete/almost complete cure (22.8% vs 4.6%; 35.5% vs 18.8%; 25.7% vs 7.1%), and clinical efficacy (31.2% vs 8.6%; 46.0% vs 23.2%; 31.4% vs 21.4%). Mycologic cure rates were also higher with efinaconazole (range: 53.4%–61.4%) vs vehicle (10.7%–30.4%). Most treatment-emergent AEs with efinaconazole were mild/moderate, with low discontinuation rates (<6%).

Conclusions: Topical efinaconazole 10% showed favorable efficacy/safety in White, Asian, and Black participants with mild-to-moderate onychomycosis. Results were generally consistent with the overall phase 3 populations and position efinaconazole as an efficacious treatment for patients, regardless of race.  .

Introduction: Lichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to treat, with current treatment options, such as topical calcineurin inhibitors, gabapentinoids, and dupilumab, commonly being ineffective, leaving patients with worsening symptoms and poor quality of life.

Case presentation: We report a case of lichen simplex chronicus in the setting of neuropathic pruritus successfully treated with nemolizumab in a 52-year-old woman. The patient did not report any side effects but reported significant improvement in quality of life.

Conclusion: Lichen simplex chronicus has a significant impairment on quality of life, as it has been linked to anxiety, depression, and poor sleep, underscoring the importance of proper disease management. Current treatment regimens for lichen simplex chronicus are often ineffective. Our observation suggests that nemolizumab may be effective in managing lichen simplex chronicus; larger studies are warranted to confirm these findings.

As cancer prevalence continues to increase in Nordic countries, the amount of dermatological adverse events, termed cutaneous adverse events (cAEs), will also increase. The Nordic European Cutaneous Oncodermatology Management (NECOM) group aims to provide evidence-based guidance on how to treat and manage cAEs with an emphasis on supportive skincare regimens to improve patients' quality of life. The presented real-world cases demonstrate the use of the previous 6 NECOM recommendations in clinical practice. Experts in supportive oncodermatology share real patient cases and cAE treatment plans to serve as a guide for future healthcare providers. The cases highlight the use of daily skincare regimens containing gentle cleansers, moisturizers, and sunscreen that help to protect the skin from severe skin toxicities and help repair the skin barrier. Patients who were prescribed a daily skincare regimen consisting of Lipikar Syndet AP+ cleanser, Lipikar Baume AP+M, Cicaplast baume B5+, and Anthelios UVMUNE SPF50+ sunscreen (La Roche-Posay) found that their cAEs were less severe and symptomatic. The products in the recommended skincare regimen have all been tested for tolerance on patients undergoing cancer treatment. NECOM advisors emphasize the importance of selecting the right skincare products that will best nourish and heal sensitive skin and encourage patients and clinicians to encourage a proactive approach to skincare before, during, and after cancer-targeted therapies.  .

Background: International Dermatology Outcome Measures (IDEOM) is a nonprofit organization committed to advancing the development and accessibility of evidence-based, consensus-driven outcome measures in dermatology. This mission is supported by a diverse group of stakeholders who collaborate to improve the research and treatment of dermatologic disease.

Summary: The 2024 IDEOM Annual Meeting was held on April 5-6, 2024. During the event, work groups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed research progress and conducted breakout sessions. This report summarizes each workgroup’s updates.

Key messages: This report outlines the key research advancements made by each IDEOM workgroup at the 2024 IDEOM Annual Meeting.  .

Many medications commonly used in dermatology come with package inserts that contain boxed warnings that are frequently not evidence-based. Boxed warnings are the most serious warnings that the US Food and Drug Administration (FDA) can issue for medications through various methods, like class labeling, despite the absence of factual, high-quality evidence. Currently, there are several medications labeled with these boxed warnings for which there is no evidence, and in many cases, there actually may exist refuting evidence. However, these warnings persist in the package inserts. This has led to much hesitancy in their use, contributing to the undertreatment, or even lack of treatment, of conditions for which these medications are efficacious. Furthermore, the negative physical and mental effects of the lack of effective treatment for patients with skin disorders are well-documented. The authors call for transparency regarding the evidence, or lack thereof, behind these boxed warnings on the part of the FDA.